CenterPoint Energy, Inc.

– Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending maintenance of orphan medicinal product designation for once-weekly TransCon CNP (navepegritide) as a treatment for achondroplasia in children. The designation would provide Ascendis benefits that include 10 years of orphan market exclusivity upon final adoption of the COMP opinion by the European Commission (EC).

CenterPoint Energy, Inc. (NYSE: CNP - Get Free Report) was the target of some unusual options trading on Tuesday. Investors acquired 10,004 put options on the stock. This is an increase of approximately 1,186% compared to the average daily volume of 778 put options. CenterPoint Energy Trading Down 3.5% Shares of CNP opened at $41.04 on

Dominion Energy (NYSE: D - Get Free Report) and CenterPoint Energy (NYSE: CNP - Get Free Report) are both large-cap utilities companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Volatility and Risk Dominion Energy has a

CenterPoint Energy increased its 10-year capital plan by $4 billion. The company expects annual rate base growth of over 14% through 2030.